Extract from the letter to the editor by Manica Balasegaram, Executive Director, GARDP
We agree with the Jan. 19 editorial “Congress should not wait for the end of the antibiotic era” and its call to develop new antibiotics through incentives that support public- and private-sector efforts. The Global Antibiotic Research and Development Partnership (GARDP), which I lead, was created in 2016 to accelerate the development and access of treatments for the most difficult-to-treat infections.